Trypanocidal activity of aziridinyl nitrobenzamide prodrugs

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4246-4252

  Bot, Chris ^a   Hall, Belinda S ^a   Bashir, Noosheen ^a   Taylor, Martin C ^b   Helsby, Nuala A ^c   Wilkinson, Shane R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTITRYPANOSOMAL AGENT; AZIRIDINYLBENZOQUINONE DERIVATIVE; BENZNIDAZOLE; LUCIFERASE; NICOTINAMIDE RIBOSIDE; NIFURTIMOX; NITROREDUCTASE;

AMASTIGOTE; ANIMAL CELL; ARTICLE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME SPECIFICITY; GENE EXPRESSION; IC 50; LIFE CYCLE; MAMMAL; NONHUMAN; PARASITE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SCREENING; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ANIMALS; BENZAMIDES; CERCOPITHECUS AETHIOPS; INHIBITORY CONCENTRATION 50; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS; VERO CELLS;

EID: 77957374117     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00800-10     Document Type: Article

References (56)

1. Adagu, I. S., D. Nolder, D. C. Warhurst, and J. F. Rossignol. 2002. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 49:103-111.
2. Alsford, S., T. Kawahara, L. Glover, and D. Horn. 2005. Tagging a T. brucei RRNA locus improves stable transfection efficiency and circumvents inducible expression position effects. Mol. Biochem. Parasitol. 144:142-148.
3. Barrett, M. P., R. J. Burchmore, A. Stich, J. O. Lazzari, A. C. Frasch, J. J. Cazzulo, and S. Krishna. 2003. The trypanosomiases. Lancet 362:1469-1480.
4. Bern, C., and S. P. Montgomery. 2009. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49:e52-e54.
5. Brun, R., J. Blum, F. Chappuis, and C. Burri. 2010. Human African trypanosomiasis. Lancet 375:148-159.
6. Buckner, F. S., C. L. Verlinde, A. C. La Flamme, and W. C. Van Voorhis. 1996. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob. Agents Chemother. 40:2592-2597.
7. Chandor, A., S. Dijols, B. Ramassamy, Y. Frapart, D. Mansuy, D. Stuehr, N. Helsby, and J. L. Boucher. 2008. Metabolic activation of the antitumor drug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by NO synthases. Chem. Res. Toxicol. 21:836-843.
8. Checchi, F., P. Piola, H. Ayikoru, F. Thomas, D. Legros, and G. Priotto. 2007. Nifurtimox plus eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl. Trop. Dis. 1:e64.
9. Chen, S., R. Knox, K. Wu, P. S. Deng, D. Zhou, M. A. Bianchet, and L. M. Amzel. 1997. Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse. J. Biol. Chem. 272:1437-1439.
10. Chen, Y., and L. Hu. 2009. Design of anticancer prodrugs for reductive activation. Med. Res. Rev. 29:29-64.
11. Chung-Faye, G., D. Palmer, D. Anderson, J. Clark, M. Downes, J. Baddeley, S. Hussain, P. I. Murray, P. Searle, L. Seymour, P. A. Harris, D. Ferry, and D. J. Kerr. 2001. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 7:2662-2668.
12. De Conti, R., D. A. Oliveira, A. M. A. P. Fernandes, P. S. Melo, J. A. Rodriguez, M. Haun, S. L. De Castro, A. R. M. Souza-Brito, and N. Duran. 1998. Application of a multi-endpoint cytotoxicity assay to the trypanocidal compounds 2-propen-1-amine derivatives and determination of their acute toxicity. In Vitro Mol. Toxicol. 11:153-160. (Pubitemid 28419855)
13. Denny, W. A. 2003. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotechnol. 2003:48-70. (Pubitemid 36828274)
14. Docampo, R., R. P. Mason, C. Mottley, and R. P. Muniz. 1981. Generation of free radicals induced by nifurtimox in mammalian tissues. J. Biol. Chem. 256:10930-10933.
15. Engel, J. C., K. K. Ang, S. Chen, M. R. Arkin, J. H. McKerrow, and P. S. Doyle. 2010. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease. Antimicrob. Agents Chemother. 54:3326-3334.
16. Ferreira, R. C., and L. C. Ferreira. 1986. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz. J. Med. Biol. Res. 19:19-25.
17. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
18. Gascon, J., C. Bern, and M. J. Pinazo. 2010. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 115:22-27.
19. Grunberg, E., and E. H. Titsworth. 1973. Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with five-membered rings. Annu. Rev. Microbiol. 27:317-346.
20. Hall, B. S., X. Wu, L. Hu, and S. R. Wilkinson. 2010. Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 54:1193-1199.
21. Helsby, N. A., G. J. Atwell, S. Yang, B. D. Palmer, R. F. Anderson, S. M. Pullen, D. M. Ferry, A. Hogg, W. R. Wilson, and W. A. Denny. 2004. Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. J. Med. Chem. 47:3295-3307.
22. Helsby, N. A., D. M. Ferry, A. V. Patterson, S. M. Pullen, and W. R. Wilson. 2004. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer 90:1084-1092.
23. Helsby, N. A., S. J. Wheeler, F. B. Pruijn, B. D. Palmer, S. Yang, W. A. Denny, and W. R. Wilson. 2003. Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. Chem. Res. Toxicol. 16:469-478.
24. Hirumi, H., and K. Hirumi. 1989. Continuous cultivation of Trypanosoma brucei blood stream forms in a medium containing a low concentration of serum protein without feeder cell layers. J. Parasitol. 75:985-989.
25. Jameson, M. B., D. Rischin, M. Pegram, J. Gutheil, A. V. Patterson, W. A. Denny, and W. R. Wilson. 2010. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. Cancer Chemother. Pharmacol. 65:791-801.
26. Kelly, J. M., H. M. Ward, M. A. Miles, and G. Kendall. 1992. A shuttle vector which facilitates the expression of transfected genes in Trypanosoma cruzi and Leishmania. Nucleic Acids Res. 20:3963-3969.
27. Kendall, G., A. F. Wilderspin, F. Ashall, M. A. Miles, and J. M. Kelly. 1990. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase does not conform to the 'hotspot' topogenic signal model. EMBO J. 9:2751-2758.
28. Knox, R. J., F. Friedlos, P. J. Biggs, W. D. Flitter, M. Gaskell, P. Goddard, L. Davies, and M. Jarman. 1993. Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitrosobenzamide, a novel DNA crosslinking agent derived from CB1954. Biochem. Pharmacol. 46:797-803.
29. Knox, R. J., F. Friedlos, T. Marchbank, and J. J. Roberts. 1991. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 42:1691-1697.
30. Knox, R. J., F. Friedlos, R. F. Sherwood, R. G. Melton, and G. M. Anlezark. 1992. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44:2297-2301.
31. Knox, R. J., T. C. Jenkins, S. M. Hobbs, S. Chen, R. G. Melton, and P. J. Burke. 2000. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 60:4179-4186.
32. Korba, B. E., A. B. Montero, K. Farrar, K. Gaye, S. Mukerjee, M. S. Ayers, and J. F. Rossignol. 2008. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77:56-63.
33. Martinez-Calvillo, S., I. Lopez, and R. Hernandez. 1997. pRIBOTEX expression vector: a pTEX derivative for a rapid selection of Trypanosoma cruzi transfectants. Gene 199:71-76.
34. Moraga, A. A., and U. Graf. 1989. Genotoxicity testing of antiparasitic nitrofurans in the Drosophila wing somatic mutation and recombination test. Mutagenesis 4:105-110.
35. Moreno, S. N., R. P. Mason, and R. Docampo. 1984. Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria. Evidence of an outer membrane-located nitroreductase. J. Biol. Chem. 259:6298-6305.
36. Muller, J., J. Wastling, S. Sanderson, N. Muller, and A. Hemphill. 2007. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob. Agents Chemother. 51:1979-1986.
37. Murta, S. M., R. T. Gazzinelli, Z. Brener, and A. J. Romanha. 1998. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol. 93:203-214.
38. Nixon, J. E., A. Wang, J. Field, H. G. Morrison, A. G. McArthur, M. L. Sogin, B. J. Loftus, and J. Samuelson. 2002. Evidence for lateral transfer of genes encoding ferredoxins, nitroreductases, NADH oxidase, and alcohol dehydrogenase 3 from anaerobic prokaryotes to Giardia lamblia and Entamoeba histolytica. Eukaryot. Cell 1:181-190.
39. Pal, D., S. Banerjee, J. Cui, A. Schwartz, S. K. Ghosh, and J. Samuelson. 2009. Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob. Agents Chemother. 53:458-464.
40. Patel, P., J. G. Young, V. Mautner, D. Ashdown, S. Bonney, R. G. Pineda, S. I. Collins, P. F. Searle, D. Hull, E. Peers, J. Chester, D. M. Wallace, A. Doherty, H. Leung, L. S. Young, and N. D. James. 2009. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Mol. Ther. 17:1292-1299. (Author's correction, 17:1302.)
41. Peterson, F. J., R. P. Mason, J. Hovsepian, and J. L. Holtzman. 1979. Oxygen-sensitive and -insensitive nitroreduction by Escherichia coli and rat hepatic microsomes. J. Biol. Chem. 254:4009-4014.
42. Priotto, G., C. Fogg, M. Balasegaram, O. Erphas, A. Louga, F. Checchi, S. Ghabri, and P. Piola. 2006. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin. Trials 1:e39.
43. Priotto, G., S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, E. Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W. Mutangala, G. Pohlig, C. Schmid, U. Karunakara, E. Torreele, and V. Kande. 2009. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374:56-64.
44. Priotto, G., S. Kasparian, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, and U. Karunakara. 2007. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin. Infect. Dis. 45:1435-1442.
45. Race, P. R., A. L. Lovering, S. A. White, J. I. Grove, P. F. Searle, C. W. Wrighton, and E. I. Hyde. 2007. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. J. Mol. Biol. 368:481-492.
46. Rodriques Coura, J., and S. L. de Castro. 2002. A critical review on Chagas disease chemotherapy. Mem. Inst. Oswaldo Cruz 97:3-24.
47. Saulnier Sholler, G. L., L. Brard, J. A. Straub, L. Dorf, S. Illeyne, K. Koto, S. Kalkunte, M. Bosenberg, T. Ashikaga, and R. Nishi. 2009. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J. Pediatr. Hematol. Oncol. 31:187-193.
48. Saulnier Sholler, G. L., S. Kalkunte, C. Greenlaw, K. McCarten, and E. Forman. 2006. Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J. Pediatr. Hematol. Oncol. 28:693-695.
49. Schofield, C. J., J. Jannin, and R. Salvatella. 2006. The future of Chagas disease control. Trends Parasitol. 22:583-588.
50. Sokolova, A. Y., S. Wyllie, S. Patterson, S. L. Oza, K. D. Read, and A. H. Fairlamb. 2010. Cross-resistance to nitro-drugs and implications for the treatment of human African trypanosomiasis. Antimicrob. Agents Chemother. 54:2893-2900.
51. Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. H. Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966.
52. Tang, M. H., N. A. Helsby, W. R. Wilson, and M. D. Tingle. 2005. Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. Toxicology 216:129-139.
53. Taylor, M. C., and J. M. Kelly. 2006. pTcINDEX: a stable tetracycline-regulated expression vector for Trypanosoma cruzi. BMC Biotechnol. 6:32.
54. Wilkinson, S. R., M. C. Taylor, D. Horn, J. M. Kelly, and I. Cheeseman. 2008. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl. Acad. Sci. U. S. A. 105:5022-5027.
55. Wu, K., R. Knox, X. Z. Sun, P. Joseph, A. K. Jaiswal, D. Zhang, P. S. Deng, and S. Chen. 1997. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch. Biochem. Biophys. 347:221-228.
56. Zacks, M. A. 2007. Impairment of cell division of Trypanosoma cruzi epimastigotes. Mem. Inst. Oswaldo Cruz 102:111-115.